Hanmi To Step Up Global Drug Development As Lilly Returns BTK Rights
Following Lilly’s decision to return rights to a BTK inhibitor it had licensed in from Hanmi, the South Korean pharma considers independently developing the molecule for other indications and vows to speed up development of other global drug programs.
You may also be interested in...
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
Lilly noted strong growth for new products, but gains seen in the fourth quarter included older products with limited potential going forward. That puts even more pressure on the R&D pipeline and the company's revised guidance, but executives were optimistic about future growth drivers.